Enrique Alvarez, MD, PhD
Associate Professor, Neurology

Photo
Download CV
Medical Schools:
  • MD, University of Colorado Denver Health Sciences Center (2006)
  • PhD, University of Colorado Denver Health Sciences Center (2004)
Graduate School :
  • MS, Washington University In St. Louis (2013)
Undergraduate School:
  • BS, North Dakota State University (ND) (1997)
Internship:
  • University of Colorado (2007)
Residency:
  • Washington University in St. Louis, Psychiatry (2010)
Fellowships:
  • Washington University in St. Louis, Neurology (2013)
Languages: English, Spanish
Department: Neurology

Professional Titles

  • Assistant Medical Director, Neurology

Publications

  • Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Aug 6. [Epub ahead of print] PubMed PMID: 32767538
  • Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020 Aug 6. [Epub ahead of print] PubMed PMID: 32767531
  • Mañago MM, Kline PW, Alvarez E, Christiansen CL. Trunk and pelvis movement compensation in people with multiple sclerosis: Relationships to muscle function and gait performance outcomes. Gait Posture. 2020 May;78:48-53. PubMed PMID: 32200163
  • Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2020 Feb;38:101508. PubMed PMID: 31715503
  • Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Aug 18;46:102454. [Epub ahead of print] PubMed PMID: 33045496
  • Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020;11:1045. PubMed PMID: 33071934
  • Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Jan 11. [Epub ahead of print] PubMed PMID: 30635477
  • Medina LD, Torres S, Alvarez E, Valdez B, Nair KV. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms. Mult Scler J Exp Transl Clin. 2019 Oct-Dec;5(4):2055217319885986. PubMed PMID: 31819803
  • Almuklass AM, Capobianco RA, Feeney DF, Alvarez E, Enoka RM. Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Mult Scler Relat Disord. 2019 Nov 6;38:101508. [Epub ahead of print] PubMed PMID: 31715503
  • Col N, Alvarez E, Springmann V, Ionete C, Berrios Morales I, Solomon A, Kutz C, Griffin C, Tierman B, Livingston T, Patel M, van Leeuwen D, Ngo L, Pbert L. A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. MDM Policy Pract. 2019 Jul-Dec;4(2):2381468319879134. PubMed PMID: 31667351
  • Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15;407:116498. PubMed PMID: 31644992
  • Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov;36:101402. PubMed PMID: 31542710
  • Khan M, Ney DE, Kleinschmidt-DeMasters BK, Horton L, Alvarez E, Piquet AL. CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab. Neurol Clin Pract. 2019 Jun;9(3):273-276. PubMed PMID: 31341717
  • Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 Jul 15;332:187-197. PubMed PMID: 31077854
  • Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019 Mar 14;7(1). PubMed PMID: 30875812
  • Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 Feb;6(2):252-262. PubMed PMID: 30847358
  • Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD. Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes. Mult Scler J Exp Transl Clin. 2019 Jan-Mar;5(1):2055217319827618. PubMed PMID: 30800417
  • Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A. Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes. Neurol Ther. 2019 Jun;8(1):109-119. PubMed PMID: 30706431
  • Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Feb 12;92(7):e723-e732. PubMed PMID: 30635477
  • Medina LD, Torres S, Alvarez E, Valdez B, Nair KV. Patient-reported outcomes in multiple sclerosis: Validation of the Quality of Life in Neurological Disorders (Neuro-QoL™) short forms. Mult Scler J Exp Transl Clin. 2019 Oct-Dec;5(4):2055217319885986. PubMed PMID: 31819803
  • Col N, Alvarez E, Springmann V, Ionete C, Berrios Morales I, Solomon A, Kutz C, Griffin C, Tierman B, Livingston T, Patel M, van Leeuwen D, Ngo L, Pbert L. A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. MDM Policy Pract. 2019 Jul-Dec;4(2):2381468319879134. PubMed PMID: 31667351
  • Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15;407:116498. PubMed PMID: 31644992
  • Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov;36:101402. PubMed PMID: 31542710
  • Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, Kutz C, Morales IB, Griffin C, Ngo LH, Jones DE, Phillips G, Hopson A, Pbert L. Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. Int J MS Care. 2018 Nov-Dec;20(6):260-267. PubMed PMID: 30568563
  • Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2018 Nov 20;27:383-390. [Epub ahead of print] PubMed PMID: 30502644
  • Alvarez E, Mowry EM. We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes. Mult Scler. 2018 Oct 22;:1352458518794061. [Epub ahead of print] PubMed PMID: 30346221
  • Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2018 Oct 3;27:65-73. [Epub ahead of print] PubMed PMID: 30342416
  • Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med. 2018 Aug 30;379(9):846-855. PubMed PMID: 30157388
  • Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug;8(4):292-301. PubMed PMID: 30140580
  • Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 Jul 15;390:89-93. PubMed PMID: 29801915
  • Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. J Neuroimaging. 2018 Jul;28(4):399-405. PubMed PMID: 29749661
  • Almuklass AM, Davis L, Hamilton LD, Hebert JR, Alvarez E, Enoka RM. Pulse Width Does Not Influence the Gains Achieved With Neuromuscular Electrical Stimulation in People With Multiple Sclerosis: Double-Blind, Randomized Trial. Neurorehabil Neural Repair. 2018 Jan;32(1):84-93. PubMed PMID: 29366377
  • Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2018 Jan;38(1):44-55. PubMed PMID: 28806143
  • Col NF, Solomon AJ, Springmann V, Ionete C, Alvarez E, Tierman B, Kutz C, Morales IB, Griffin C, Ngo LH, Jones DE, Phillips G, Hopson A, Pbert L. Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. Int J MS Care. 2018 Nov-Dec;20(6):260-267. PubMed PMID: 30568563
  • Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep;3(3):2055217317725102. PubMed PMID: 28839949
  • Col NF, Solomon AJ, Springmann V, Garbin CP, Ionete C, Pbert L, Alvarez E, Tierman B, Hopson A, Kutz C, Berrios Morales I, Griffin C, Phillips G, Ngo LH. Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. Med Decis Making. 2017 Aug 1;:272989X17724434. [Epub ahead of print] PubMed PMID: 28806143
  • Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e339. PubMed PMID: 28382320
  • Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28;89(22):2238-2244. PubMed PMID: 29093070
  • Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep;3(3):2055217317725102. PubMed PMID: 28839949
  • Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e339. PubMed PMID: 28382320
  • Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2015 Feb 24;84(8):861. PubMed PMID: 25713115
  • Hampton CW, Galperin D, Alvarez E, West MS. Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma. Neurol Neuroimmunol Neuroinflamm. 2015 Jun;2(3):e82. PubMed PMID: 25798447
  • Seibert JB, Alvarez E. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology. 2015 Feb 24;84(8):861. PubMed PMID: 25713115
  • Alvarez E. Should we start evaluating intrathecal IgM production clinically?. Eur J Neurol. 2015 Aug;22(8):1143-4. PubMed PMID: 25557488
  • Alvarez E. Should we start evaluating intrathecal IgM production clinically?. Eur J Neurol. 2014 Dec 30. [Epub ahead of print] PubMed PMID: 25557488
  • Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013 Dec;19(14):1938-42. PubMed PMID: 24277735
  • Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler. 2013 Aug;19(9):1204-8. PubMed PMID: 23322500
  • Wang LH, Bucelli RC, Patrick E, Rajderkar D, Alvarez Iii E, Lim MM, Debruin G, Sharma V, Dahiya S, Schmidt RE, Benzinger TS, Ward BA, Ances BM. Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. J Neurol. 2013 Feb;260(2):498-506. PubMed PMID: 22968768
View All (48 Total) View Less

Professional Memberships

  • American Academy of Neurology (AAN), Member
  • Colorado Society of Clinical Neurologists (CSCN), Member
  • Society for Neuroscience (SFN), Member
  • American Medical Association (AMA), Member
  • America Society for Neural Transplantation and Repair (ASNTR), Member
  • Rocky Mountain Regional Neuroscience Group (RMRNG), Member
  • Colorado Medical Association, Member

Practice Locations

Neurosciences Center - Anschutz
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080

UCH - Anschutz Outpatient Pavilion
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Neurology, Board Certification (2012)
  • Neuroimmunology
Conditions & Treatments
  • Brain and Nervous System
  • Brain and Nervous System - Multiple Sclerosis
Clinical Interests
Multiple Sclerosis and other neuroimmunological disorders of the central nervous system including neuromyelitis optica, neurosarcoidosis, and autoantibody/paraneoplastic syndromes.

Care Philosophy
Multidisciplinary care for MS and related diseases. We believe in aggressive treatment of MS with disease modifying and symptomatic therapies.

General Information

Medical Schools:
  • MD, University of Colorado Denver Health Sciences Center (2006)
  • PhD, University of Colorado Denver Health Sciences Center (2004)
Graduate Schools:
  • MS, Washington University In St. Louis (2013)
Undergraduate Schools:
  • BS, North Dakota State University (ND) (1997)
Internships:
  • University of Colorado (2007)
Residency Programs:
  • Washington University in St. Louis, Psychiatry (2010)
Fellowships:
  • Washington University in St. Louis, Neurology (2013)
Download CV
Languages: English, Spanish
Department: Neurology
;